One thing I was wondering is whether / when we will see the stockpiled manufactured treatments added to the balance sheet. Correct me if I am wrong but I've seen multilple annual reports where investment and costs associated with product manufacturing were recorded. I believe I may have also seen a comment from a CFO that until approval was granted the manufactured product would not be added to the balance sheet, was I dreaming this? Anyone have any insights?
-
- There are more pages in this discussion • 1,253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
0.065(3.62%) |
Mkt cap ! $2.376B | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.89 | $1.83 | $8.165M | 4.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6744 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 5904 | 3 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |